🔗 Share this article

While America proceeds with unprecedented adjustments to its immunization recommendations, one figure has emerged unexpectedly: Tracy Beth Høeg, a US-based sports medicine doctor and epidemiologist who initially gained attention by casting doubt on Covid vaccines in the global health crisis and has zeroed in on potential fatalities following Covid immunization in her recent tenure at the Food and Drug Administration.

Scheduled Shifts to Pediatric Immunization Schedule

Agency leaders planned to reveal radical changes to the pediatric vaccine schedule recently, bringing the US with the Danish national calendar, according to reports – a significant shift that would put the US out of alignment with a large portion of the world with no evidence for improved outcomes. The planned update has been pushed back until the coming year.

Rather than Vinay Prasad, Høeg is scheduled to address the audience at the gathering. She was recently named interim head of the FDA’s drug evaluation center, the fifth person to lead the center this year.

A New Direction at the FDA

This interim role may indicate a strengthened alliance between the pharmaceutical and vaccine branches as Høeg and Prasad strengthen their influence at the regulatory agency – and it signals a greater focus upon dismantling already-approved vaccines at the FDA.

Høeg has frequently advocated for discontinuing some childhood vaccine recommendations in the US to become more similar to the Danish model, a nation with nationalized medicine and a number of inhabitants roughly the population of the state of Wisconsin.

So far statements, she has kept her attention on vaccination policy – traditionally the purview of Dr. Prasad, head of the FDA’s CBER – rather than drug regulation.

Concerns Over Expertise

The appointee has little discernible experience in pharmaceutical research, oversight or administrative roles, which has been standard for previous heads of the CBER. She has worked at the FDA as a top consultant to the commissioner and the vaccine center since March.

“It seems she lacks to have the necessary background” for overseeing the CDER, said Jonathan Howard. “She lacks experience running a clinical trial. She lacks experience in running a large organization. She has no expertise in drug approvals.”

Previous heads of the center would “understand laws and regulations and the underlying principles of pharmaceutical innovation”, commented a former acting FDA commissioner. “Clearly, she has not acquired the type of experience that previous people who headed the center have had.”

CDER has an enormous portfolio at the FDA, the former commissioner emphasized.

“The public just zeroes in on the innovative therapies, but the generic program approves a multitude of off-brand pharmaceuticals. There is also a biosimilars program, OTC medication office and more, and all of those have to be managed,” Dr. Woodcock explained. “The responsibility you don’t keep your eye on, that is the part that I always told people is going to cause problems.”

Additionally, a substantial management element to the role, which manages in excess of 5,000 staff members. “It’s a enormous administrative position, if you execute it properly,” Woodcock added.

Agency Reaction and Disputed Programs

In response to questions about Dr. Høeg's credentials and whether this selection represents greater collaboration among agency officials on immunizations, a press secretary said that the “concerns are based on inaccurate assumptions”.

“Her resume aligns with the responsibilities of her role,” the spokesperson explained, citing the time Dr. Høeg spent advising the agency head on “medication safety and approval science, including computational safety modeling and shot safety tracking”.

As the temporary head, Høeg assumes responsibility for the agency head's new priority voucher program, a disputed expedited drug-approval program that allegedly worried her preceding directors. “By what process are these drugs being picked for this fast-track system? Who takes the calls?” Howard asked. “There is a lot of confidentiality happening at the regulatory body right now.”

Overall, he stated, “the FDA appears to be shifting towards more relaxed oversight of pharmaceuticals, aside from shots.”

Established History on Vaccines

Regarding immunizations, Høeg has a more documented, if concerning, past, Howard observe. She released a analysis using non-validated volunteer-provided data to determine the incidence of heart inflammation after COVID-19 immunization. She consulted for the state of Florida top health official Dr. Joseph Ladapo, who reportedly have modified findings to suggest Covid vaccines are more dangerous than they are.

Part of her “wish list” for the current government featured changing rules for new vaccines and ending “non-essential” vaccines, she remarked following the vote on a audio program. At the agency, Høeg has allegedly floated the idea of barring adolescent males from getting Covid vaccinations.

“She’s an thorough ideologue who commences with her preconceived notions and reverse-engineers to retrofit the evidence in a very disingenuous, untruthful way,” Howard stated.

Consolidating Power and a “Revenge Tour”

Høeg aligned with fellow dissenters, {like|